That, and with respect to:
> Alzheimer’s sounds like a good candidate, or near-fatal diseases (6-month-to-live cancer) - you literally have nothing to lose!
But others have a lot to lose. No matter how experimental the application and how much consent and oversight - if the drug is being used on people before finishing all testing and without taking all necessary precautions, you increase the risk of side or adverse effects. That in turn will likely delay the approval of the drug for all patients.
So in the end, a couple of people get experimental treatment but might delay the treatment for a large group of people. That's no easy trade-off, and is certainly not a sign for a broken system.